ConductScience.org, home

Paper35011990

Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study.

Imamura R and 12 others. J Clin Med, 2022. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study. Papers, record 35011990. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35011990

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study.
PubMed
Journal
J Clin Med
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.64
iCite
Revised in PubMed
2022-01-14
PubMed

Authors13

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Imamura RRyoichihttps://orcid.org/0000-0002-8782-9852
2Tanaka RRyo
3Taniguchi AAyumu
4Nakazawa SShigeaki
5Kato TTaigo
6Yamanaka KKazuaki
7Namba-Hamano TTomoko
8Kakuta YYoichi
9Abe TToyofumi
10Tsutahara KKoichi
11Takao TTetsuya
12Kishikawa HHidefumi
13Nonomura NNorio

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References43

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129100424Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study.Oncotarget2017https://conductscience.org/library/papers/29100424PubMed
220455882Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients.Am J Transplant2010https://conductscience.org/library/papers/20455882PubMed
39603954Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability.J Biol Chem1998https://conductscience.org/library/papers/9603954PubMed
425088685A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.Am J Transplant2014https://conductscience.org/library/papers/25088685PubMed
518256371Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference.Clin J Am Soc Nephrol2008https://conductscience.org/library/papers/18256371PubMed
623222892Time on dialysis and cancer risk after kidney transplantation.Transplantation2013https://conductscience.org/library/papers/23222892PubMed
730155929Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma.Int J Cancer2019https://conductscience.org/library/papers/30155929PubMed
819155967The role of mTOR inhibitors in the management of posttransplant malignancy.Transplantation2009https://conductscience.org/library/papers/19155967PubMed
916286900mTOR inhibition and its effect on cancer in transplantation.Transplantation2005https://conductscience.org/library/papers/16286900PubMed
1015548972Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study.Transplantation2004https://conductscience.org/library/papers/15548972PubMed
1124684741Conversion to mammalian target of rapamycin inhibitors increases risk of de novo donor-specific antibodies.Transpl Int2014https://conductscience.org/library/papers/24684741PubMed
1215122205The TOR pathway: a target for cancer therapy.Nat Rev Cancer2004https://conductscience.org/library/papers/15122205PubMed
1317538086Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.N Engl J Med2007https://conductscience.org/library/papers/17538086PubMed
1427445164Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients.Clin J Am Soc Nephrol2016https://conductscience.org/library/papers/27445164PubMed
1522343319Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression.Cancer Lett2012https://conductscience.org/library/papers/22343319PubMed
1622420843Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer.Am J Transplant2012https://conductscience.org/library/papers/22420843PubMed
1720642495Calcineurin inhibitor sparing regimens using m-target of rapamycin inhibitors: an opportunity to improve cardiovascular risk following kidney transplantation?Transpl Int2011https://conductscience.org/library/papers/20642495PubMed
1818094377Reduced exposure to calcineurin inhibitors in renal transplantation.N Engl J Med2007https://conductscience.org/library/papers/18094377PubMed
1926686199The benefits of cancer screening in kidney transplant recipients: a single-center experience.Cancer Med2016https://conductscience.org/library/papers/26686199PubMed
2016162203Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients.Am J Transplant2005https://conductscience.org/library/papers/16162203PubMed

See all 43 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42970195Long-term outcomes of a quadruple calcineurin inhibitor-minimization regimen with everolimus introduced 3-6 months after kidney transplantation.Clin Exp Nephrol2026https://conductscience.org/library/papers/42970195PubMed
41583478Risk factors for cancer and the importance of screening in adult recipients of living-donor kidney transplant.Front Immunol2025https://conductscience.org/library/papers/41583478PubMed
41340872Astragalin: A promising herbal compound with broad anticancer potential (Review).Oncol Lett2026https://conductscience.org/library/papers/41340872PubMed
39589637Analysis of research trends and hotspots in the primary treatment of end-stage renal disease.Int Urol Nephrol2025https://conductscience.org/library/papers/39589637PubMed
39533221Sirolimus-induced pulmonary toxicity without recurrence more than 8 years after everolimus replacement in a renal transplant patient with recurrent skin SCC: a case report.BMC Nephrol2024https://conductscience.org/library/papers/39533221PubMed
37892805Difficult-to-Treat Rejections in Kidney Transplant Recipients: Our Experience with Everolimus-Based Quadruple Maintenance Therapy.J Clin Med2023https://conductscience.org/library/papers/37892805PubMed
35887954Special Issue: New Advances in Kidney Transplantation.J Clin Med2022https://conductscience.org/library/papers/35887954PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35011990

GET https://conductscience.org/api/papers/v1/35011990/references?page=2